Skip to main content
. 2023 Jan 16;19(3):981–993. doi: 10.7150/ijbs.79852

Figure 1.

Figure 1

ATM depletion sensitizes tumors to anti-Gal-9 therapy in CT26 syngeneic mouse model. A. RT-qPCR analysis of ATM mRNA in vector control and ATM-KD CT26. B. A diagram of treatment strategy. BALB/c mice were inoculated with vector control (VC) or ATM-KD CT26 cells and then treated with isotype or anti-Gal-9 antibody (100μg /dose for 3 times). C. Tumor growth curves of individual BALB/c mice inoculated with VC or ATM-KD CT26 cells and subjected to indicated treatment (n = 6 mice/group). D. Average tumor growth of mice inoculated with VC or ATM-KD CT26 cells and subjected to indicated treatments. Error bars represent SEM of the means. Anti-Gal-9 antibody treatment schedule is indicated by arrows. E. Survival curves of BALB/c mice inoculated with VC or ATM-KD CT26 cells and subjected to the indicated treatments (n = 6 mice/group). n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.